Tlc Biopharmaceuticals, Inc.

Taiwan Liposome Company, Ltd.

Taiwan Lipsome Company, Ltd.

Tcl Biopharmaceuticals, Inc.

Luke S S Guo

Keelung Hong

Yun-Long Tseng

Po-Chun Chang

Sheue-Fang Shih

Chih-Chiang Tsai

Hong-Hui Lin

Hao-Wen Kao

Yi-Yu Lin

Hong-Hul Lin

Jun-Jen Liu

Chi-Chun Lai

Hsiu-Li Song

Provided is an anesthetic composition for locally administrating an amide-type anesthetic into a subject in need thereof. The anesthetic composition has multilamellar vesicles with entrapped amide-type anesthetic prepared by hydrating a highly entrapped lipid structure comprising an amide-type anesthetic and a lipid mixture with an aqueous buffer solution at a pH higher than 5.5. Also provided is a method to prepare an anesthetic composition using a simpler and more feasible process for large-scale manufacture and for providing a high molar ratio of amide-type anesthetic to phospholipid content as compared to the prior art. This anesthetic composition has a prolonged duration of efficacy adapted to drug delivery.

Sustained-release anesthetic compositions and methods of preparation thereof

The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.

Pharmaceutical composition for intraarticular delivery

An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.

Drug delivery system containing phospholipid and cholesterol

Pharmaceutical compositions for intraarticular delivery

Methods of treating arthritis

Ophthalmic drug delivery system containing phospholipid and cholesterol

The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof, a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.

Pharmaceutical compositions to reduce complications of ocular steroid

The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.

The invention provides a liposome composition for delivering high pay-load of a therapeutic agent to neovascularization sites of the eyes in a patient in need thereof. The liposome composition for entrapping the therapeutic agent comprises a particle forming component composed of a variety of vesicle-forming lipids, and an agent-carrying component able to form a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction; wherein the liposome composition comprising the therapeutic agent has a mean particle diameter of about 30 to 200 nm and may accumulate at the neovascularization sites of the eyes 24 hours after the intravenous administration of the liposome composition comprising the therapeutic agent to the patient. A method for delivering the therapeutic agent to the eyes in a patient with this liposome composition is also provided.

Liposome composition for delivery of a therapeutic agent to eyes

The present invention provides novel monoclonal antibodies with a high binding affinity to all five isoforms of human VEGF.

Growing community of inventors

South San Francisco, CA, United States of America

Luke S S Guo